Abstract
Anti-angiogenic therapy has recently been added to the panel of cancer therapeutics, but predictive biomarkers of response are still not available. In animal models, anti-angiogenic therapy causes tumor starvation by increasing hypoxia and impairing nutrients supply. It is thus conceivable that angiogenesis inhibition causes remarkable metabolic perturbations in tumors, although they remain largely uncharted. We review here recent acquisitions about metabolic effects of angiogenesis blockade in tumors and discuss the possibility that some metabolic features of tumor cells - i.e. their dependency from glucose as primary energy substrate - might affect tumor responses to anti-VEGF treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 925-931 |
| Number of pages | 7 |
| Journal | Biochimie |
| Volume | 94 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2012 |
Fingerprint
Keywords
- Angiogenesis
- Anti-angiogenic therapy
- Glycolysis
- LKB1-AMPK pathway
ASJC Scopus subject areas
- Biochemistry
Cite this
Metabolic effects of anti-angiogenic therapy in tumors. / Zulato, Elisabetta; Curtarello, Matteo; Nardo, Giorgia; Indraccolo, Stefano.
In: Biochimie, Vol. 94, No. 4, 04.2012, p. 925-931.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Metabolic effects of anti-angiogenic therapy in tumors
AU - Zulato, Elisabetta
AU - Curtarello, Matteo
AU - Nardo, Giorgia
AU - Indraccolo, Stefano
PY - 2012/4
Y1 - 2012/4
N2 - Anti-angiogenic therapy has recently been added to the panel of cancer therapeutics, but predictive biomarkers of response are still not available. In animal models, anti-angiogenic therapy causes tumor starvation by increasing hypoxia and impairing nutrients supply. It is thus conceivable that angiogenesis inhibition causes remarkable metabolic perturbations in tumors, although they remain largely uncharted. We review here recent acquisitions about metabolic effects of angiogenesis blockade in tumors and discuss the possibility that some metabolic features of tumor cells - i.e. their dependency from glucose as primary energy substrate - might affect tumor responses to anti-VEGF treatment.
AB - Anti-angiogenic therapy has recently been added to the panel of cancer therapeutics, but predictive biomarkers of response are still not available. In animal models, anti-angiogenic therapy causes tumor starvation by increasing hypoxia and impairing nutrients supply. It is thus conceivable that angiogenesis inhibition causes remarkable metabolic perturbations in tumors, although they remain largely uncharted. We review here recent acquisitions about metabolic effects of angiogenesis blockade in tumors and discuss the possibility that some metabolic features of tumor cells - i.e. their dependency from glucose as primary energy substrate - might affect tumor responses to anti-VEGF treatment.
KW - Angiogenesis
KW - Anti-angiogenic therapy
KW - Glycolysis
KW - LKB1-AMPK pathway
UR - http://www.scopus.com/inward/record.url?scp=84857450316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84857450316&partnerID=8YFLogxK
U2 - 10.1016/j.biochi.2012.01.001
DO - 10.1016/j.biochi.2012.01.001
M3 - Article
C2 - 22245704
AN - SCOPUS:84857450316
VL - 94
SP - 925
EP - 931
JO - Biochimie
JF - Biochimie
SN - 0300-9084
IS - 4
ER -